Project Grant R01FD007597
Award Date
9/5/24
Completion Date
8/31/28
Dollars Obligated
$742K
Funding Federal Agency
Office of Medical Products and Tobacco
Awarding Federal Agency
FDA Office of Acquisition and Grant Services
Federal Grant Program
93.103
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15222, USA
Similar Awards
This federal Project Grant award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) provides $882,247 to the University of Pittsburgh to conduct a Phase 2 clinical trial evaluating the efficacy of interferon-gamma (IFN-γ) and donor lymphocyte infusion (DLI) for treating relapsed myeloid malignancies after allogeneic stem cell transplantation. The study aims to enroll 45 participants and compare outcomes to synthetic control cohorts. Sub-awards have been made to the Fred...
This Project Grant award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) provides $400,000.00 to The Children's Hospital of Philadelphia (CHOP) to establish the PKDNET initiative. The goal of PKDNET is to create a robust data resource to identify a research-ready cohort of children with autosomal recessive polycystic kidney disease (ARPKD) and collect high-quality natural history data. This will help address key barriers to conducting clinical trials for ARPKD,...
This $194,172 Project Grant, awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) on August 1, 2025, will fund research by Dr. Ruben Colman at Stanford University to elucidate the relationship between microbial metabolites and anti-TNF pharmacokinetics in pediatric Crohn's disease. The goal is to develop machine learning models that can predict endoscopic and transmural healing based on these pharmacodynamic markers, thereby enhancing precision medicine...
This federal Project Grant award of $630,847 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports research conducted by Children's Mercy Hospital in Kansas City, Missouri to study the role of the SIGIRR gene in regulating intestinal barrier function and preventing necrotizing enterocolitis (NEC) in preterm infants. The key focus areas include...
This Project Grant awarded by the Food and Drug Administration (FDA) Research program (CFDA 93.103) provides $1,300,000 to the Sloan-Kettering Institute for Cancer Research to conduct a Phase 2A/2B clinical trial evaluating the use of the interferon-gamma neutralizing monoclonal antibody emapalumab as a prophase therapy for pediatric patients with newly diagnosed acquired aplastic anemia. The trial aims to assess if this prophase can help identify patients most likely to respond favorably to...
The Department of Health and Human Services' Food and Drug Administration awarded The Johns Hopkins University a $3.2 million Project Grant under the FDA Research program (CFDA 93.103) for the period of September 15, 2022 through August 31, 2026. The grant aims to improve clinical trials for Ataxia Telangiectasia (A-T), a rare genetic disease, through three specific objectives: prospectively testing A-T severity stratification using genetic, phenotypic and laboratory markers; using RNA...
This Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the federal Child Health and Human Development Extramural Research program (CFDA 93.865), will provide $309,496 to Duke University over a 2-year period ending June 19, 2027. The project aims to elucidate the mechanisms by which key transcription factors (MAFB, CMAF, and BLIMP1) regulate neonatal intestinal nutrient absorption and immune development. Through genetic...
This federal Project Grant award of $1,160,229, provided by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under CFDA 93.865 Child Health and Human Development Extramural Research, will fund a randomized trial comparing transpyloric to gastric feeding in very preterm infants with bronchopulmonary dysplasia (BPD). The research aims to determine whether transpyloric feeding safely and effectively reduces gastroesophageal reflux disease (GERD) in this...
This federal Project Grant award of $151,643, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research on developing and evaluating Proteolysis Targeting Chimeras (PROTACs) to stabilize hypoxia-inducible factors (HIFs) as a potential therapeutic approach for inflammatory bowel disease (IBD). The principal investigator, Dr. Ornelas Sanchez, and his...
This Project Grant award of $186,221 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop personalized sepsis therapeutics for pediatric patients. The key objectives are to: 1) Augment sepsis phenotypes using high-frequency physiologic data to identify additional subtypes and predict disease progression; 2) Retrospectively identify signs of bloodstream infection prior to traditional diagnostic signs...